banner news

Singapore, October 30, 2020 – Credo Diagnostics Biomedical Pte. Ltd., the leader of point-of-care rapid molecular diagnostic, announced today it has received CE-Mark for the VitaPCR™ Influenza A&B/SARS-CoV-2 assay, a rapid molecular diagnostic test for qualitative detection of the viruses causing COVID-19, Flu A, and Flu B infections from a single patient sample. The three-in-one test is designed for use on any of Credo Diagnostics Biomedical's thousands of VitaPCR™ systems deployed worldwide, with results delivered in 20 minutes at the point-of-care.

 

“Going into the Flu season as clinicians across the northern hemisphere are battling with the ‘second wave’ of COVID-19 infections will inevitably complicate the already devastating coronavirus pandemic,” said Sofiane Bennacer, Head of Business Development at Credo Diagnostics Biomedical. “COVID-19, Flu A, and Flu B patients present similar symptoms, however they require very different approaches for triage, patient management, and treatment. The ability to quickly and accurately detect and differentiate the three viruses is crucial to support the healthcare system and avoid its collapse.”

 

The versatile VitaPCR™ platform delivers rapid results without highly trained personnel while increasing daily testing capacity. The platform can be deployed in various settings such as clinical laboratories, ER, clinics, and other high-risk locations. It was successfully implemented at the Charles De Gaulle airport in Paris, allowing symptomatic travelers to be tested on-site and receive their results in 20 minutes.

 

To support the anticipated rise in demand for the VitaPCR™ Influenza A&B/SARS-CoV-2 Assay, Credo Diagnostics Biomedical has announced the expansion of its production capacity to reach a monthly output of millions of tests starting from October. 

 

“With the collision of the Flu season with the coronavirus pandemic, there is a real concern from healthcare providers that there will be a further shortage of testing supplies and testing personnel,” said Dr. Winston Wong Jr., Chairman of Credo Diagnostics Biomedical. “Our goal is to provide stable supplies of COVID-19 and Influenza tests to better serve healthcare providers and patients worldwide, while empowering clinicians to make rapid and accurate decisions on isolation, treatment, and contact tracing.”

 

The VitaPCR™ Influenza A&B/SARS-CoV-2 Assay has already begun to ship in Europe through Credo Diagnostics Biomedical’s distribution network. 

 

 


 

About Credo Diagnostics Biomedical Pte. Ltd.

Credo Diagnostics Biomedical develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas of Animal Health, Human Health, and Human Wellness. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.

 

CONTACT

We at Credo Diagnostics Biomedical pioneer accessible diagnostic platforms to improve the lives of those we love. We believe providing the right information to the right people at the right time leads to better outcomes.